Some Hydrazones of 2‐Aroylamino‐3‐methylbutanohydrazide: Synthesis, Molecular Modeling Studies, and Identification as Stereoselective Inhibitors of HIV‐1
Identifieur interne : 000B29 ( Main/Exploration ); précédent : 000B28; suivant : 000B30Some Hydrazones of 2‐Aroylamino‐3‐methylbutanohydrazide: Synthesis, Molecular Modeling Studies, and Identification as Stereoselective Inhibitors of HIV‐1
Auteurs : Esra Tatar [Turquie] ; Lkay Küçükgüzel [Turquie] ; Dirk Daelemans [Belgique] ; Tanaji T. Talele [États-Unis] ; Neerja Kaushik-Basu [États-Unis] ; Erik De Clercq [Belgique] ; Christophe Pannecouque [Belgique]Source :
- Archiv der Pharmazie [ 0365-6233 ] ; 2013-02.
English descriptors
- Teeft :
- Acid hydrazide, Acylhydrazone, Acylhydrazones, Alkyl, Amide, Amino acid side chains, Anal, Antiviral, Antiviral activity, Assay, Biol, Bioorg, Calcd, Cell culture, Chem, Clercq, Compound, Crude product, Default parameters, Derivative, Dextran sulfate, Docking, Gmbh, Hplc, Hydrazide, Hydrazine hydrate, Hydrazone, Hydrazone derivatives, Hydrazones, Iiib, Iiib nnrtir, Information table, Inhibitor, Kgaa, Ltered, Marmara university, Moiety, Nnrti, Nnrti mode, Novel site, Online version, Petroleum ether, Pharm, Reaction medium, Stereoselective, Stereoselective inhibitors, Tatar, Test compound, Test compounds, Transcriptase, Verlag, Verlag gmbh, Weinheim, Weinheim arch, Weinheim hydrazones, Wild type.
Abstract
In accordance with our antiviral drug development attempt, acylhydrazone derivatives bearing amino acid side chains were synthesized for the evaluation of their antiviral activity against various types of viruses. Among these compounds, 8S, 11S, and 12S showed anti‐HIV‐1 activity with a 50% inhibitory concentration (IC50) = 123.8 µM (selectivity index, SI > 3), IC50 = 12.1 µM (SI > 29), IC50 = 17.4 µM (SI > 19), respectively. Enantiomers 8R, 11R, and 12R were inactive against the HIV‐1 strain IIIB. Hydrazones 8S, 11S, and 12S which were active against HIV‐1 wild type showed no inhibition against a double mutant NNRTI‐resistant strain (K103N;Y181C). Molecular docking calculations of R‐ and S‐enantiomers of 8, 11, and 12 were performed using the hydrazone‐bound novel site of HIV‐1 RT.
Acylhydrazone derivatives bearing amino acid side chains were synthesized for the evaluation of their antiviral activity against various types of viruses. 8 S, 11 S, and 12 S showed anti‐HIV‐1 activity with a 50% inhibitory concentration of 123.8, 12.1, and 17.4 µM, respectively. Enantiomers 8R, 11R, and 12 R were inactive against HIV‐1 strain IIIB. Molecular docking calculations of the R‐ and S‐enantiomers of 8, 11, and 12 were performed using the hydrazone‐bound novel site of HIV‐1 RT.
Url:
DOI: 10.1002/ardp.201200311
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000866
- to stream Istex, to step Curation: 000846
- to stream Istex, to step Checkpoint: 000041
- to stream Main, to step Merge: 000B31
- to stream Main, to step Curation: 000B29
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Some Hydrazones of 2‐Aroylamino‐3‐methylbutanohydrazide: Synthesis, Molecular Modeling Studies, and Identification as Stereoselective Inhibitors of HIV‐1</title><author><name sortKey="Tatar, Esra" sort="Tatar, Esra" uniqKey="Tatar E" first="Esra" last="Tatar">Esra Tatar</name></author><author><name sortKey="Kucukguzel, Lkay" sort="Kucukguzel, Lkay" uniqKey="Kucukguzel " first=" Lkay" last="Küçükgüzel"> Lkay Küçükgüzel</name></author><author><name sortKey="Daelemans, Dirk" sort="Daelemans, Dirk" uniqKey="Daelemans D" first="Dirk" last="Daelemans">Dirk Daelemans</name></author><author><name sortKey="Talele, Tanaji T" sort="Talele, Tanaji T" uniqKey="Talele T" first="Tanaji T." last="Talele">Tanaji T. Talele</name></author><author><name sortKey="Kaushik Asu, Neerja" sort="Kaushik Asu, Neerja" uniqKey="Kaushik Asu N" first="Neerja" last="Kaushik-Basu">Neerja Kaushik-Basu</name></author><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name></author><author><name sortKey="Pannecouque, Christophe" sort="Pannecouque, Christophe" uniqKey="Pannecouque C" first="Christophe" last="Pannecouque">Christophe Pannecouque</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7F0B79C3003E6A746C16DD9A4FBEC596D1488B8D</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/ardp.201200311</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-XDF0L29D-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000866</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000866</idno><idno type="wicri:Area/Istex/Curation">000846</idno><idno type="wicri:Area/Istex/Checkpoint">000041</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000041</idno><idno type="wicri:doubleKey">0365-6233:2013:Tatar E:some:hydrazones:of</idno><idno type="wicri:Area/Main/Merge">000B31</idno><idno type="wicri:Area/Main/Curation">000B29</idno><idno type="wicri:Area/Main/Exploration">000B29</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Some Hydrazones of 2‐Aroylamino‐3‐methylbutanohydrazide: Synthesis, Molecular Modeling Studies, and Identification as Stereoselective Inhibitors of HIV‐1</title><author><name sortKey="Tatar, Esra" sort="Tatar, Esra" uniqKey="Tatar E" first="Esra" last="Tatar">Esra Tatar</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Marmara University, Haydarpaşa, İstanbul</wicri:regionArea><wicri:noRegion>İstanbul</wicri:noRegion></affiliation></author><author><name sortKey="Kucukguzel, Lkay" sort="Kucukguzel, Lkay" uniqKey="Kucukguzel " first=" Lkay" last="Küçükgüzel"> Lkay Küçükgüzel</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Marmara University, Haydarpaşa, İstanbul</wicri:regionArea><wicri:noRegion>İstanbul</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Turquie</country></affiliation><affiliation></affiliation></author><author><name sortKey="Daelemans, Dirk" sort="Daelemans, Dirk" uniqKey="Daelemans D" first="Dirk" last="Daelemans">Dirk Daelemans</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Talele, Tanaji T" sort="Talele, Tanaji T" uniqKey="Talele T" first="Tanaji T." last="Talele">Tanaji T. Talele</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Kaushik Asu, Neerja" sort="Kaushik Asu, Neerja" uniqKey="Kaushik Asu N" first="Neerja" last="Kaushik-Basu">Neerja Kaushik-Basu</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biochemistry and Molecular Biology, UMDNJ‐New Jersey Medical School, Newark, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Pannecouque, Christophe" sort="Pannecouque, Christophe" uniqKey="Pannecouque C" first="Christophe" last="Pannecouque">Christophe Pannecouque</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Rega Institute for Medical Research, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Archiv der Pharmazie</title><title level="j" type="alt">ARCHIV DER PHARMAZIE</title><idno type="ISSN">0365-6233</idno><idno type="eISSN">1521-4184</idno><imprint><biblScope unit="vol">346</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="140">140</biblScope><biblScope unit="page" to="153">153</biblScope><biblScope unit="page-count">14</biblScope><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><date type="published" when="2013-02">2013-02</date></imprint><idno type="ISSN">0365-6233</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0365-6233</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acid hydrazide</term><term>Acylhydrazone</term><term>Acylhydrazones</term><term>Alkyl</term><term>Amide</term><term>Amino acid side chains</term><term>Anal</term><term>Antiviral</term><term>Antiviral activity</term><term>Assay</term><term>Biol</term><term>Bioorg</term><term>Calcd</term><term>Cell culture</term><term>Chem</term><term>Clercq</term><term>Compound</term><term>Crude product</term><term>Default parameters</term><term>Derivative</term><term>Dextran sulfate</term><term>Docking</term><term>Gmbh</term><term>Hplc</term><term>Hydrazide</term><term>Hydrazine hydrate</term><term>Hydrazone</term><term>Hydrazone derivatives</term><term>Hydrazones</term><term>Iiib</term><term>Iiib nnrtir</term><term>Information table</term><term>Inhibitor</term><term>Kgaa</term><term>Ltered</term><term>Marmara university</term><term>Moiety</term><term>Nnrti</term><term>Nnrti mode</term><term>Novel site</term><term>Online version</term><term>Petroleum ether</term><term>Pharm</term><term>Reaction medium</term><term>Stereoselective</term><term>Stereoselective inhibitors</term><term>Tatar</term><term>Test compound</term><term>Test compounds</term><term>Transcriptase</term><term>Verlag</term><term>Verlag gmbh</term><term>Weinheim</term><term>Weinheim arch</term><term>Weinheim hydrazones</term><term>Wild type</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In accordance with our antiviral drug development attempt, acylhydrazone derivatives bearing amino acid side chains were synthesized for the evaluation of their antiviral activity against various types of viruses. Among these compounds, 8S, 11S, and 12S showed anti‐HIV‐1 activity with a 50% inhibitory concentration (IC50) = 123.8 µM (selectivity index, SI > 3), IC50 = 12.1 µM (SI > 29), IC50 = 17.4 µM (SI > 19), respectively. Enantiomers 8R, 11R, and 12R were inactive against the HIV‐1 strain IIIB. Hydrazones 8S, 11S, and 12S which were active against HIV‐1 wild type showed no inhibition against a double mutant NNRTI‐resistant strain (K103N;Y181C). Molecular docking calculations of R‐ and S‐enantiomers of 8, 11, and 12 were performed using the hydrazone‐bound novel site of HIV‐1 RT.</div><div type="abstract" xml:lang="en">Acylhydrazone derivatives bearing amino acid side chains were synthesized for the evaluation of their antiviral activity against various types of viruses. 8 S, 11 S, and 12 S showed anti‐HIV‐1 activity with a 50% inhibitory concentration of 123.8, 12.1, and 17.4 µM, respectively. Enantiomers 8R, 11R, and 12 R were inactive against HIV‐1 strain IIIB. Molecular docking calculations of the R‐ and S‐enantiomers of 8, 11, and 12 were performed using the hydrazone‐bound novel site of HIV‐1 RT.</div></front></TEI><affiliations><list><country><li>Belgique</li><li>Turquie</li><li>États-Unis</li></country><region><li>New Jersey</li><li>État de New York</li></region></list><tree><country name="Turquie"><noRegion><name sortKey="Tatar, Esra" sort="Tatar, Esra" uniqKey="Tatar E" first="Esra" last="Tatar">Esra Tatar</name></noRegion><name sortKey="Kucukguzel, Lkay" sort="Kucukguzel, Lkay" uniqKey="Kucukguzel " first=" Lkay" last="Küçükgüzel"> Lkay Küçükgüzel</name><name sortKey="Kucukguzel, Lkay" sort="Kucukguzel, Lkay" uniqKey="Kucukguzel " first=" Lkay" last="Küçükgüzel"> Lkay Küçükgüzel</name></country><country name="Belgique"><noRegion><name sortKey="Daelemans, Dirk" sort="Daelemans, Dirk" uniqKey="Daelemans D" first="Dirk" last="Daelemans">Dirk Daelemans</name></noRegion><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><name sortKey="Pannecouque, Christophe" sort="Pannecouque, Christophe" uniqKey="Pannecouque C" first="Christophe" last="Pannecouque">Christophe Pannecouque</name></country><country name="États-Unis"><region name="État de New York"><name sortKey="Talele, Tanaji T" sort="Talele, Tanaji T" uniqKey="Talele T" first="Tanaji T." last="Talele">Tanaji T. Talele</name></region><name sortKey="Kaushik Asu, Neerja" sort="Kaushik Asu, Neerja" uniqKey="Kaushik Asu N" first="Neerja" last="Kaushik-Basu">Neerja Kaushik-Basu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B29 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B29 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7F0B79C3003E6A746C16DD9A4FBEC596D1488B8D
|texte= Some Hydrazones of 2‐Aroylamino‐3‐methylbutanohydrazide: Synthesis, Molecular Modeling Studies, and Identification as Stereoselective Inhibitors of HIV‐1
}}
| This area was generated with Dilib version V0.6.33. |  |